KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group.

Christopher B Jackson, Wei Xue, Abha A Gupta, Amira Qumseya, Roshni Dasgupta, Christine E Hill-Kayser, Aaron C Spalding, David A Rodeberg, Douglas J Harrison, Rajkumar Venkatramani, Suzanne L Wolden

Int J Radiat Oncol Biol Phys 123(1) 54-62

PMID40185209
PMCIDPMC12353335
DOI10.1016/j.ijrobp.2025.03.038
发表日期2025-04-04
入排依据:The study is a randomized phase III trial in human oncology reporting original results, but it evaluates a radiation therapy dose escalation strategy and does not involve a drug-containing intervention. The primary endpoint is local failure, reported as a percentage rate at a fixed time point, not a time-to-event analysis with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the inclusion criteria for a drug intervention and a primary/key secondary time-to-event efficacy endpoint.
KM panel re-extraction failed
摘要

摘要

PURPOSE: To evaluate local failure (LF) rates for patients with intermediate-risk rhabdomyosarcoma treated on the Children's Oncology Group ARST1431 clinical trial, the first and largest international, phase 3 randomized study to use FOXO1 fusion status for risk stratification. To improve local control, radiation therapy (RT) dose was increased to 59.4 Gy for patients with tumors >5 cm and residual gross disease at the time of RT. METHODS AND MATERIALS: For the 297 patients included, LF was defined as progression or relapse at the primary site. The rate of LF was calculated 3-years after enrollment. RESULTS: LF for group 3, FOXO1 fusion-positive patients (n = 58) compared with fusion-negative patients (n = 175) was 10.7% versus 21.5%, respectively (P = .08). The LF rate for patients with tumors >5 cm at diagnosis (n = 180; 24.4%) was higher than that of patients with tumors ≤5 cm at diagnosis (n = 117; 9.8%), P = .002. The risk of LF for patients who received proton (n = 99) versus photon RT (n = 126) was not different (16.1% vs 15.9%, P = .8). For the 75 patients with tumors >5 cm at diagnosis and gross disease at the time of RT, the boost to 59.4 Gy did not improve the 3-year LF rate compared with that of patients who did not receive the boost (29.7% vs 16.1%, P = .6). For patients with group 3/4 disease, those who underwent delayed primary excision (n = 72) had a lower LF rate compared with those who had RT alone (n = 151) (5.8% vs 19.7%, P < .01). CONCLUSIONS: On ARST1431, tumors >5 cm at diagnosis had poor local control despite dose escalation to 59.4 Gy. Proton and photon RT had equivalent local control. For select patients, delayed primary excision significantly improved local control.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2.

Cumulative incidence of local failure for group III/IV patients with tumors >5cm at diagnosis with gross disease after induction chemotherapy, stratified by receipt of RT boost to 59.4 Gy.

RT_Boost

Cumulative Incidence of Local Failure

Figure 2. · Panel RT_Boost

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel RT_Boost 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.A) Cumulative incidence of local failure for clinical group III patients stratified by fusion status. B) Cumulative incidence of local failure for all clinical groups, stratified by RT modality (protons or photons). C) Cumulative incidence of local failure for all patients stratified by tumor size at diagnosis, ≤5 cm or >5cm at diagnosis.
非 KM Figure
Figure 3.Cumulative incidence of local failure for group III/IV patients who received RT alone or DPE, with or without RT.
非 KM Figure
Figure 4CONSORT Diagram
非 KM Figure